Trial Profile

A 2-Year, Dose Range-Finding, Adaptive-Design Study of the Effects of SCH 527123 in Subjects With Moderate to Severe COPD (P05575AM2)

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 11 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Navarixin (Primary)
Indications Chronic obstructive pulmonary disease
Focus Adverse reactions; Therapeutic Use
Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.; Schering-Plough Research Institute

Most Recent Events

07 Jun 2019 This trial has been completed in France, according to European Clinical Trials Database.
23 Feb 2012 Status changed from active, no longer recruiting to discontinued as reported by European Clinical Trials Database.
22 Sep 2011 Planned End Date changed from 1 Sep 2012 to 1 Nov 2011 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com